Cover Image
市場調查報告書

Salix Pharmaceuticals Ltd.的產品平台分析

Salix Pharmaceuticals Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 207943
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
Salix Pharmaceuticals Ltd.的產品平台分析 Salix Pharmaceuticals Ltd. - Product Pipeline Review - 2014
出版日期: 2014年05月30日 內容資訊: 英文 45 Pages
簡介

Salix Pharmaceuticals Ltd.是特殊醫藥品企業,主要開發、銷售消化器官疾病的預防及治療用處方藥。

本報告提供Salix Pharmaceuticals Ltd.上的治療藥開發平台現狀及各開發階段比較分析,提供藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,以及最新的企業新聞和發表,後期階段及中止計劃的相關資訊等。

Salix Pharmaceuticals Ltd.的基本資料

Salix Pharmaceuticals Ltd.概要

  • 主要資訊
  • 企業資料

Salix Pharmaceuticals Ltd.:R&D概要

  • 主要的治療範圍

Salix Pharmaceuticals Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Salix Pharmaceuticals Ltd.:開發中產品概況

  • 位於最終階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 位於第三階段的產品/聯合治療模式
  • 位於臨床實驗階段的開發中產品
    • 位於第二階段的產品/聯合治療模式

Salix Pharmaceuticals Ltd.:藥物簡介

  • budesonide
  • methylnaltrexone bromide
  • rifaximin
  • budesonide ER
  • RHB-106
  • SAN-300

Salix Pharmaceuticals Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各類型分子
  • 各作用機制

Salix Pharmaceuticals Ltd.:最近的開發平台趨勢

Salix Pharmaceuticals Ltd.:暫停中的計劃

Salix Pharmaceuticals Ltd.:企業發表

Salix Pharmaceuticals Ltd.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04880CDB

Global Markets Direct's, 'Salix Pharmaceuticals Ltd. - Product Pipeline Review - 2014', provides an overview of the Salix Pharmaceuticals Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Salix Pharmaceuticals Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Salix Pharmaceuticals Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Salix Pharmaceuticals Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Salix Pharmaceuticals Ltd.'s pipeline products

Reasons to buy

  • Evaluate Salix Pharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Salix Pharmaceuticals Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Salix Pharmaceuticals Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Salix Pharmaceuticals Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Salix Pharmaceuticals Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Salix Pharmaceuticals Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Salix Pharmaceuticals Ltd. Snapshot
    • Salix Pharmaceuticals Ltd. Overview
    • Key Information
    • Key Facts
  • Salix Pharmaceuticals Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Salix Pharmaceuticals Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Salix Pharmaceuticals Ltd. - Pipeline Products Glance
    • Salix Pharmaceuticals Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Salix Pharmaceuticals Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
  • Salix Pharmaceuticals Ltd. - Drug Profiles
    • budesonide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methylnaltrexone bromide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rifaximin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • budesonide ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RHB-106
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAN-300
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Salix Pharmaceuticals Ltd. - Pipeline Analysis
    • Salix Pharmaceuticals Ltd. - Pipeline Products by Target
    • Salix Pharmaceuticals Ltd. - Pipeline Products by Route of Administration
    • Salix Pharmaceuticals Ltd. - Pipeline Products by Molecule Type
    • Salix Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action
  • Salix Pharmaceuticals Ltd. - Recent Pipeline Updates
  • Salix Pharmaceuticals Ltd. - Dormant Projects
  • Salix Pharmaceuticals Ltd. - Company Statement
  • Salix Pharmaceuticals Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Salix Pharmaceuticals Ltd., Key Information
  • Salix Pharmaceuticals Ltd., Key Facts
  • Salix Pharmaceuticals Ltd. - Pipeline by Indication, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2014
  • Salix Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2014
  • Salix Pharmaceuticals Ltd. - Partnered Products in Pipeline, 2014
  • Salix Pharmaceuticals Ltd. - Partnered Products/ Combination Treatment Modalities, 2014
  • Salix Pharmaceuticals Ltd. - Pre-Registration, 2014
  • Salix Pharmaceuticals Ltd. - Phase III, 2014
  • Salix Pharmaceuticals Ltd. - Phase II, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Target, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2014
  • Salix Pharmaceuticals Ltd. - Recent Pipeline Updates, 2014
  • Salix Pharmaceuticals Ltd. - Dormant Developmental Projects,2014
  • Salix Pharmaceuticals Ltd., Subsidiaries

List of Figures

  • Salix Pharmaceuticals Ltd. - Pipeline by Top 10 Indication, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2014
  • Salix Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2014
  • Salix Pharmaceuticals Ltd. - Partnered Products in Pipeline, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Top 10 Target, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Top 10 Route of Administration, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top